Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Hill, Andrew ^a,b   Bergin, Peter ^b   Hanning, Fritha ^b   Thompson, Paul ^b   Findlay, Michael ^b   Damianovich, Dragan ^b   McKeage, Mark J ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; DYSPNEA; ELECTROMYOGRAPHY; FEMALE; HUMAN; INJECTION SITE DISCOMFORT; JAW DISEASE; JAW TIGHTNESS; LIMB PAIN; MALE; MOTOR NERVE; MOTOR NERVE CONDUCTION; MUSCLE CRAMP; NERVE EXCITABILITY; NERVE POTENTIAL; NEUROPHYSIOLOGY; NEUROTOXICITY; PARESTHESIA; SIDE EFFECT; SYMPTOMATOLOGY; THROAT TIGHTNESS; VISION; CANCER STAGING; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; HEAD AND NECK TUMOR; LUNG TUMOR; METASTASIS; MIDDLE AGED; MOTOR NEURON DISEASE; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; TOXICITY AND INTOXICATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOTOR NEURON DISEASE; NEOPLASM STAGING; NEUROPHYSIOLOGY; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77955808810     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-451     Document Type: Article

References (16)

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7:573-584. 10.1038/nrc2167, 17625587.
2. Mollman JE. Cisplatin neurotoxicity. N Engl J Med 1990, 322:126-127. 10.1056/NEJM199001113220210, 2152970.
3. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003, 30:5-13. 10.1016/S0093-7754(03)00399-3, 14523789.
4. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf 1995, 13:228-244. 10.2165/00002018-199513040-00003, 8573296.
5. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002, 20:1767-1774. 10.1200/JCO.2002.07.056, 11919233.
6. Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004, 29:387-392. 10.1002/mus.10559, 14981738.
7. Shillito P, Molenaar PC, Vincent A, Leys K, Zheng W, Vandenberg RJ, Plomp JJ, Vankempen GTH, Chauplannaz G, Wintzen AR, et al. Acquired neuromyotonia - evidence for autoantibodies directed against K+ channels of peripheral-nerves. Annals of Neurology 1995, 38:714-722. 10.1002/ana.410380505, 7486862.
8. Webster RG, Brain KL, Wilson RH, Grem JL, Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol 2005, 146:1027-1039. 10.1038/sj.bjp.0706407, 1751225, 16231011.
9. Park SB, Lin CSY, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 2009, 132:2712-2723. 10.1093/brain/awp219, 19745023.
10. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 2000, 406:25-32. 10.1016/S0014-2999(00)00667-1, 11011028.
11. Broomand A, Jerremalm E, Yachnin J, Ehrsson H, Elinder F. Oxaliplatin neurotoxicity--no general ion channel surface-charge effect. J Negat Results Biomed 2009, 8:2. 10.1186/1477-5751-8-2, 2639537, 19138416.
12. VanDijk JG, Lammers GJ, Wintzen AR, Molenaar PC. Repetitive CMAPs: Mechanisms of neural and synaptic genesis. Muscle & Nerve 1996, 19:1127-1133.
13. Engel AG, Lambert EH, Mulder DM, Torres CF, Sahashi K, Bertorini TE, Whitaker JN. A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Annals of Neurology 1982, 11:553-569. 10.1002/ana.410110603, 6287911.
14. Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ. Paclitaxel-induced neuropathy. Ann Oncol 1995, 6:489-494.
15. Gamelin L, Capitain O, Morel A, Dumont A, Traore S, Anne LB, Gilles S, Boisdron-Celle M, Gamelin E. Predictive factors of oxaliplatin neurotoxicity: The involvement of the oxalate outcome pathway. Clinical Cancer Research 2007, 13:6359-6368. 10.1158/1078-0432.CCR-07-0660, 17975148.
16. Screnci D, McKeage MJ, Galettis P, Hambley TW, Palmer BD, Baguley BC. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer 2000, 82:966-972. 10.1054/bjoc.1999.1026, 2374394, 10732773.